West Michigan Cancer Center and Institute for Blood Disorders (WMCC) named Bridget VandenBussche as interim executive director Thursday to lead the organization.
VandenBussche started with WMCC in 2011 and previously served as the director of quality improvement and risk. She has a total of 15 years in the quality improvement and public health management field, including five years at Borgess Medical Center in Kalamazoo.
"I am excited, humbled and honored to lead WMCC as medical oncology and infusion services make their long-planned transition to our partner hospitals," VandenBussche said in a release. "I look forward to working collaboratively with Borgess and Bronson to help shape the future of all of the treatment services we provide at our main campus for patients with cancer and blood disorders. The demand for radiation therapy, surgery, and gynecologic oncology services continue to grow and embrace the opportunity to work on our center's long-term strategy to serve the community's needs."
She has her bachelors in accounting from Michigan State University and is a certified professional in healthcare risk management. She also earned a basic life support certification, is back belt certified in Six Sigma, and is a Crisis Prevention Institute instructor.
"She is a perfect fit to lead to organization into the next decade as treatment options for cancer and blood disorders evolve with out changing healthcare landscape." WMCC Board Chairman John Hayden said in a release.
WMCC is a non-profit collaboration between Ascension Borgess and Bronson Healthcare Group. The organization offers comprehensive, multidisciplinary, integrative cancer and hematology treatment with an average of 4,000 new patient consults annually.